Researchers conducted the UP-TAINED study to assess the effectiveness and safety of upadacitinib for over 2 years, with patients with moderate to severe AD receiving either 15 mg or 30 mg once daily.

Tirzepatide is associated with a greater mean percent body weight reduction than semaglutide in adults with obesity or overweight and one or more related complications.

Cardiovascular disease still claims more lives than any other illness, and many adults living with obesity or type 2 diabetes carry a heavy risk of heart attack and stroke. Two medications, ...

Mepolizumab significantly reduced asthma exacerbations and oral corticosteroid use in patients with SEA, with or without CRSwNP, in a real-world setting. Improvements in lung function and asthma ...

Real-world data show ADCs benefit more diverse, older and pretreated patients, helping guide care and build confidence beyond ...

Brentuximab vedotin with CHP is effective and safe for first-line PTCL treatment, achieving an 80% overall response rate. Median progression-free survival was 39.7 months, with a 1-year overall ...

VARIPURE demonstrated strong safety outcomes with no incidence of stroke and 99.7% acute effectiveness of the VARIPULSE™ Platform in nearly 800 enrolled patientsi VARIPURE, a SECURE substudy, is a ...

Sensitive skin affects up to 70% of people globally – a figure that has risen by 68% over the past two decades – yet it remains widely overlooked and under-studied. 2,3 As more people live fast-paced ...

TOKYO and CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (BIIB) (Nasdaq ...